IRMA-International.org: Creator of Knowledge
Information Resources Management Association
Advancing the Concepts & Practices of Information Resources Management in Modern Organizations

Economic Profit vs. Social Benefit: An Approach to the Pharmaceutical Industry

Economic Profit vs. Social Benefit: An Approach to the Pharmaceutical Industry
View Sample PDF
Author(s): M. Mercedes Galán-Ladero (University of Extremadura, Spain)and M. Ángeles Galán-Ladero (Hospital Universitario Virgen de Valme, Andalusian Health Service, Spain)
Copyright: 2021
Pages: 21
Source title: Management and Marketing for Improved Competitiveness and Performance in the Healthcare Sector
Source Author(s)/Editor(s): José Duarte Santos (Polytechnic Institute of Gaya, Portugal)and Inês Veiga Pereira (ISCAP, Polytechnic Institute of Porto, Portugal)
DOI: 10.4018/978-1-7998-7263-4.ch002

Purchase

View Economic Profit vs. Social Benefit: An Approach to the Pharmaceutical Industry on the publisher's website for pricing and purchasing information.

Abstract

There is currently a wide-ranging debate on whether it is ethical for pharmaceutical companies to profit and obtain large economic benefits by patenting and controlling the sale of essential medicines that can save thousands of lives, or, on the contrary, whether these medicines should be considered social products and offered at low prices so that anyone, in any country in the world, regardless of their purchasing power, can have access to them. This debate has intensified since health was considered a fundamental human right by the World Health Organization (WHO) and was expressly included in the Sustainable Development Goals (SDGs) adopted by the United Nations (specifically, in Goal 3: “Health and Well-Being”). Consequently, the overall objective of this chapter is to reflect on these questions: Should economic interests prevail over social ones in the case of essential life-saving medicines? Should the fundamental right to health prevail over the right granted by a patent? How far should corporate social responsibility (CSR) go in the pharmaceutical industry?

Related Content

Kakhaber Djakeli. © 2024. 25 pages.
Nugzar Todua, Charita Jashi, Nia Todua. © 2024. 16 pages.
Mohamad Zreik. © 2024. 19 pages.
Agnieszka Jadwiga Wójcik-Czerniawska, Zbigniew Grzymała. © 2024. 17 pages.
Aditya Prasad, Ashwani Panesar. © 2024. 26 pages.
Iza Gigauri. © 2024. 12 pages.
V. Sangeetha, A. Mamatha, M. Vaneeta, K. Beena. © 2024. 15 pages.
Body Bottom